Merus (NASDAQ:MRUS – Free Report) – Equities researchers at Leerink Partnrs lifted their Q3 2023 earnings estimates for Merus in a note issued to investors on Monday, August 7th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will earn ($0.80) per share for the quarter, up from their previous estimate of ($0.95). The consensus estimate for Merus’ current full-year earnings is ($3.52) per share. Leerink Partnrs also issued estimates for Merus’ Q4 2023 earnings at ($0.81) EPS, FY2023 earnings at ($3.21) EPS, FY2024 earnings at ($4.04) EPS, FY2025 earnings at ($4.02) EPS and FY2026 earnings at ($0.64) EPS.
Other research analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and set a $48.00 target price on shares of Merus in a research report on Tuesday. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $35.00 target price on shares of Merus in a research note on Friday, April 14th. Guggenheim raised their price target on shares of Merus from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Tuesday. Citigroup boosted their price objective on shares of Merus from $47.00 to $48.00 in a research report on Thursday, May 18th. Finally, SVB Securities raised their target price on shares of Merus from $35.00 to $48.00 and gave the stock an “outperform” rating in a research report on Monday, April 17th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Merus has an average rating of “Moderate Buy” and an average target price of $44.56.
Merus Trading Down 0.3 %
MRUS stock opened at $22.89 on Thursday. Merus has a 12 month low of $12.03 and a 12 month high of $28.11. The stock has a market cap of $1.07 billion, a PE ratio of -5.93 and a beta of 0.80. The company has a 50-day moving average price of $25.54 and a 200 day moving average price of $21.32.
Hedge Funds Weigh In On Merus
Institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its position in Merus by 107.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,811 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 938 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Merus during the first quarter valued at about $58,000. Deutsche Bank AG bought a new position in Merus in the fourth quarter worth about $45,000. Citigroup Inc. lifted its position in shares of Merus by 29.4% during the fourth quarter. Citigroup Inc. now owns 3,530 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 803 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of Merus by 278.1% in the 1st quarter. UBS Group AG now owns 3,732 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 2,745 shares in the last quarter. 78.29% of the stock is owned by hedge funds and other institutional investors.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Featured Articles
- Five stocks we like better than Merus
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Best Renewable Energy Stocks as Summer Heat Builds
- Industrial Products Stocks Investing
- Kinder Morgan Shines With Dividend Yield, Cash Flow, Buybacks
- What is the FTSE 100 index?
- 3 Stocks to Buy No Matter Which Way Inflation Moves
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.
